Matrixx starts recall of Zicam nasal products

Matrixx Initiatives has started to notify U.S. customers of its recall of nasal versions of its zinc-containing Zicam cold remedy after more than 130 consumers reported losing their sense of smell after using the products.

On June 16, the FDA warned Matrixx to stop selling two intranasal versions of its zinc-containing Zicam cold remedy. The FDA also urged consumers to stop taking Zicam, which is sold over-the-counter.

Matrixx said on Wednesday that it was in the process of formally notifying retailers, wholesalers and distributors of its recall of all Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs, even as the company “vigorously disagrees” with the U.S. Food and Drug Administration over allegations that the products are not safe and were unlawfully marketed.

The company “is conducting this recall because of its desire to cooperate with the FDA,” Matrixx said.

Separately, Matrixx said on Tuesday that it had received an informal inquiry from the U.S. Securities and Exchange Commission about last week’s FDA warning letter relating to Zicam.

NEW YORK (Reuters)